Q-omics provides the consensus-scored PSMB4 profile across patient tissues and cancer cell-line models. PSMB4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PSMB4 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, PSMB4 protein abundance shows 23,361 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, and HNSC as cancer lineages where PSMB4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMB4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMB4 survival associations across molecular data types. PSMB4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMB4 RNA expression–survival associations across cancer types. High PSMB4 expression shows unfavorable associations in ACC, KIRP, UVM, KICH, LIHC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PSMB4 RNA expression.
This table summarizes PSMB4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PSMB4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMB4 shows higher tumor expression in HNSC, KIRC, BLCA, COAD, LIHC and LUAD. The HNSC box plot shows higher PSMB4 RNA expression in tumor versus normal tissue (log2 FC = +1.274, t-test p < 0.001).
This table shows molecular features associated with PSMB4 in patient tissues and cancer cell lines. In patient samples, PSMB4 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMB4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
